Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)
Year: 2013
Type: article
Study design: Study Protocol
Abstract: BACKGROUND: Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD. METHODS: Herein, we describe the design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON) trial, a multinational, multicenter, double-blind, randomized, placebo-controlled Phase 3 trial designed to determine whether long-term administration of bardoxolone methyl (on a background of standard therapy, including RAAS inhibitors) safely reduces renal and cardiac morbidity and mortality. RESULTS: The primary composite endpoint is time-to-first occurrence of either end-stage renal disease or cardiovascular death. Secondary endpoints include the change in eGFR and time to occurrence of cardiovascular events. CONCLUSION: BEACON will be the first event-driven trial to evaluate the effect of an oral antioxidant and anti-inflammatory drug in advanced CKD.
Source: American Journal of Nephrology
DOI: 10.1159/000346948
Authors: Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, Paul Audhya, George L. Bakris, Melanie Chin, Melissa Krauth, Hiddo J. Lambers Heerspink, Colin J. Meyer, John J. McMurray, Hans-Henrik Parving, Pablo E. Pergola, Giuseppe Remuzzi, Robert D. Toto, Nosratola D. Vaziri, Christoph Wanner, David G. Warnock, Janet Wittes, Glenn M. Chertow
Institutions: University Medical Center Groningen, University of Groningen, SHOWA Medical University, Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indiana University, Reata Pharmaceuticals (United States), University of Chicago, University of Chicago Medical Center, University of Glasgow, University of Copenhagen, Rigshospitalet, Renal Associates P. A., Mario Negri Institute for Pharmacological Research, The University of Texas Southwestern Medical Center, University of California, Irvine, University of Würzburg, University of Alabama at Birmingham, Statistics Collaborative, Stanford Medicine, Stanford University
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Keywords: bardoxolone methyl, chronic kidney disease, type 2 diabetes, Nrf2 activation, oxidative stress, anti-inflammatory therapy, antioxidant therapy, kidney disease progression, end-stage renal disease, cardiovascular mortality, estimated glomerular filtration rate, renin-angiotensin-aldosterone system inhibitors, BEACON trial
Open Access status: bronze
OpenAlex ID: W2071792689
